Telix Pharmaceuticals (TLX) Invested Capital (2023 - 2025)
Telix Pharmaceuticals has reported Invested Capital over the past 3 years, most recently at $405.0 million for Q4 2025.
- Quarterly Invested Capital fell 45.63% to $405.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $744.9 million through Dec 2024, up 587.81% year-over-year, with the annual reading at $405.0 million for FY2025, 45.63% down from the prior year.
- Invested Capital was $405.0 million for Q4 2025 at Telix Pharmaceuticals, down from $744.9 million in the prior quarter.
- Over five years, Invested Capital peaked at $744.9 million in Q4 2024 and troughed at $108.3 million in Q4 2023.
- The 3-year median for Invested Capital is $405.0 million (2025), against an average of $419.4 million.
- Year-over-year, Invested Capital skyrocketed 587.81% in 2024 and then crashed 45.63% in 2025.
- A 3-year view of Invested Capital shows it stood at $108.3 million in 2023, then skyrocketed by 587.81% to $744.9 million in 2024, then crashed by 45.63% to $405.0 million in 2025.
- Per Business Quant, the three most recent readings for TLX's Invested Capital are $405.0 million (Q4 2025), $744.9 million (Q4 2024), and $108.3 million (Q4 2023).